HRT Financial’s LakeShore Biopharma LSB Stock Holding History

HRT Financial’s Portfolio LSB Stock Details LSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,050	Closed	-$14K	–	3229
2023 Q2	$14K	Buy	+1,050	New	+$15.5K	﹤0.01%	2142

Other funds holding LSB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

VAM

Valliance Asset Management Central, Hong Kong $864M AUM 906.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

SLM

Snow Lake Management Menlo Park, California $90.7M AUM 72.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

PAM

Pinpoint Asset Management Hong Kong $576M AUM 43.65% 1-Year Est. Return

HRT Financial's LSB Position: Q3 2023 in Review

HRT Financial sold out of LakeShore Biopharma (LSB) in Q3 2023, closing a stake of 1,050 shares — an estimated $14K sold.

HRT Financial first reported a position in LSB in Q2 2023 and held it in 1 quarter. The position peaked at $14K in Q2 2023. 12 funds tracked by Wall St. Rank hold LSB as of Q3 2023.

HRT Financial reported no remaining LakeShore Biopharma position as of Q3 2023 after selling out during the quarter.
HRT Financial sold 1,050 LakeShore Biopharma shares in Q3 2023, an estimated $14K.
HRT Financial first reported a position in LakeShore Biopharma in Q2 2023 and held it in 1 quarter.
HRT Financial's LakeShore Biopharma position peaked at $14K in Q2 2023.
12 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q3 2023.

Based on HRT Financial's 13F filing for Q3 2023, filed 13 Nov 2023.